CRISPR Therapeutics AG - Company Profile
Powered by 
All the sales intelligence you need on CRISPR Therapeutics AG in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how CRISPR Therapeutics AG fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with CRISPR Therapeutics AG.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
CRISPR Therapeutics AG (CRISPR Therapeutics) is a biotechnology company focused on developing gene-based medicines for serious human diseases. The company specialises in CRISPR/Cas9 technology to create therapeutics that can disrupt, delete, correct, and insert genes. Its major product is CASGEVY, a CRISPR-based therapy for hemoglobinopathies such as sickle cell disease and transfusion-dependent beta thalassemia. The company's products are primarily used in the healthcare industry, specifically in the treatment and prevention of both rare and common diseases. CRISPR Therapeutics collaborates with Vertex Pharmaceuticals Incorporated to advance its therapeutic programs. The company's products are used in healthcare applications, particularly in treating genetic disorders and developing advanced cellular therapies. CRISPR Therapeutics is headquartered in Zug, Switzerland.
Headquarters
Switzerland
Address
Baarerstrasse 14, Zug, CH-6300
Website
crisprtx.com
Telephone
41 41 5613279
No of Employees
393
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
CRSP (NASD)
Revenue (2024)
$3.5M
-90.6%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-58.8%
(2024 vs 2023)
Market Cap*
$5.8B
Net Profit Margin (2024)
XYZ
-1,588.1%
(2024 vs 2023)
* As of and is in US$
CRISPR Therapeutics AG premium industry data and analytics
Products and Services
| Products |
|---|
| Casgevy (exagamglogene autotemcel [exa-cel]): Transfusion-Dependent beta Thalassemia (TDT) and Sickle Cell Disease |
| Pipeline |
| CD117ADC |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In March, the company collaborated with Sirius Therapeutics to Develop Novel siRNA Therapies. |
| 2024 | Regulatory Approval | In February, the company received conditional marketing authorization to CASGEVY (exagamglogene autotemcel [exa-cel]) from the European Commission for the treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT). |
| 2023 | Regulatory Approval | In June, the company and Vertex Pharmaceuticals' Biologics License Applications were accepted by the US FDA for the investigational treatment exagamglogene autotemcel for severe sickle cell disease and transfusion-dependent beta thalassemia. |
Competitor Comparison
| Key Parameters | CRISPR Therapeutics AG | Genetix Biotherapeutics Inc | Poseida Therapeutics Inc | Sangamo Therapeutics Inc | Precision Biosciences Inc |
|---|---|---|---|---|---|
| Headquarters | Switzerland | United States of America | United States of America | United States of America | United States of America |
| City | Zug | Somerville | San Diego | Richmond | Durham |
| State/Province | Zug | Massachusetts | California | California | North Carolina |
| No. of Employees | 393 | 248 | 350 | 142 | 66 |
| Entity Type | Public | Private | Private | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Samarth Kulkarni | Chief Executive Officer; Chairman; Director | Executive Board | 2023 | - |
| Raju Prasad, Ph.D. | Chief Financial Officer | Senior Management | 2023 | - |
| Naimish Patel, M.D. | Chief Medical Officer | Senior Management | 2024 | - |
| Megan Wherry Menner | Head - Human Resources | Senior Management | - | - |
| James R. Kasinger | Secretary; General Counsel | Senior Management | 2017 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer